C3 Glomerulopathy (C3G)

Understanding C3 Glomerulopathy

C3 glomerulopathy (C3G) is a rare kidney disease. In C3G, an important part of the immune system known as the complement cascade is overactive, which results in the excessive breakdown of a protein called C3.1 These C3 breakdown products become trapped in the kidney, causing inflammation and damage to the organ.1

The signs and symptoms of C3G include blood in the urine (hematuria); dark foamy urine due to the presence of protein (proteinuria); cloudy urine due to presence of white blood cells; edema (swelling), often in the legs, although any part of the body can be affected; high blood pressure; decreased urine output; and decreased alertness.2

There are no medicines currently approved for C3G, so there is a substantial need for medicines that target the cause of the disease. C3G can lead to kidney failure within five to 10 years of diagnosis in approximately 50% of people, requiring these patients to go on dialysis or get a kidney transplant.3

Pegcetacoplan (APL-2) in C3G

Pegcetacoplan is a targeted C3 inhibitor designed to regulate uncontrolled or excessive complement activation. We believe it may have the potential to target the underlying disease process of C3G.

Interested in our clinical trials in C3G?

For clinical trial information, please email us at clinicaltrials@apellis.com.

Resources

References

  1. Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/condition/c3-glomerulopathy. Accessed November 27, 2019.
  2. Complement 3 Glomerulopathy (C3G). National Kidney Foundation Website. https://www.kidney.org/atoz/content/complement-3-glomerulopathy-c3g. Accessed November 21, 2019.
  3. C3 glomerulopathy. National Institute of Health, Genetics Home Reference. https://ghr.nlm.nih.gov/condition/c3-glomerulopathy#resources. Accessed November 21, 2019.